Prospective study of safety, immunogenicity, and efficacy of inactivated COVID-19 vaccine in tuberous sclerosis complex children on sirolimus

While sirolimus is widely used in tuberous sclerosis complex (TSC), its impact on coronavirus disease 2019 (COVID-19) vaccination remains unclear. To evaluate the safety, immunogenicity, and efficacy of inactivated COVID-19 vaccine on the children with TSC on sirolimus, we conducted a prospective co...

Full description

Bibliographic Details

Published in:	Human Vaccines & Immunotherapeutics
Main Authors:	Sufang Lin, Xia Zhao, Lin Li, Qiru Su, Weiwei Long, Xiaoqin Tian, Jinghua Ye, Bixia Yuan, Yan Hu, Jianxiang Liao, Hongbing Zhang
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2025-12-01
Subjects:	COVID-19 vaccine immunogenicity efficacy tuberous sclerosis complex sirolimus
Online Access:	https://www.tandfonline.com/doi/10.1080/21645515.2025.2535120